tiprankstipranks
Trending News
More News >
Sofwave Medical Ltd. (IL:SOFW)
:SOFW
Israel Market
Advertisement

Sofwave (SOFW) AI Stock Analysis

Compare
3 Followers

Top Page

IL:SOFW

Sofwave

(SOFW)

Rating:54Neutral
Price Target:
3,072.00
▲(12.78% Upside)
Sofwave's stock score is primarily influenced by its strong technical momentum, despite concerns over profitability and valuation. The robust upward price trend is a significant positive, but the lack of profitability and cash flow challenges weigh heavily on the overall score.

Sofwave (SOFW) vs. iShares MSCI Israel ETF (EIS)

Sofwave Business Overview & Revenue Model

Company DescriptionSofwave Medical Ltd. develops an ultrasound technology for treating fine lines and wrinkles in Israel and internationally. It offers non-invasive skin treatment aesthetic medical devices to physicians. The company was incorporated in 2015 and is based in Yokne'am Illit, Israel.
How the Company Makes MoneySofwave generates revenue primarily through the sale and distribution of its medical devices and related consumables to dermatologists, plastic surgeons, and aesthetic practitioners. The company also offers training and support services to ensure the effective use of its technology, which can contribute to additional revenue streams. Furthermore, Sofwave may engage in partnerships or collaborations with clinics and medical facilities to expand its market reach and increase device adoption. The company's earnings are influenced by the demand for non-invasive aesthetic treatments, technological advancements, and its ability to maintain strong relationships with its distribution network.

Sofwave Financial Statement Overview

Summary
Sofwave shows positive revenue growth and a strong gross profit margin, but struggles with profitability and cash flow stability. The low debt profile is a positive indicator, but negative net profit margins and declining free cash flow growth are concerning.
Income Statement
45
Neutral
Sofwave has shown a positive revenue growth rate of 10.05% in the TTM, indicating a growing market presence. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong at 76.25%, suggesting efficient production processes, but the overall profitability is hindered by high operating expenses.
Balance Sheet
50
Neutral
The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.06, indicating low leverage and reduced financial risk. However, the return on equity is negative, highlighting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a solid capital structure.
Cash Flow
40
Negative
The cash flow statement shows a concerning decline in free cash flow growth, with a significant negative growth rate of -197.34% in the TTM. Despite this, the company maintains a positive free cash flow to net income ratio, indicating some ability to convert profits into cash. The operating cash flow to net income ratio is negative, reflecting challenges in cash generation from operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue69.49M59.65M50.31M35.63M21.84M4.29M
Gross Profit52.85M45.34M37.48M26.33M16.24M2.63M
EBITDA1.11M-2.19M-6.61M-16.97M-6.43M-11.32M
Net Income-1.63M-4.55M-8.28M-19.53M-6.83M-11.69M
Balance Sheet
Total Assets44.88M43.03M43.54M46.08M60.77M4.82M
Cash, Cash Equivalents and Short-Term Investments23.50M21.62M24.42M32.01M46.22M2.64M
Total Debt1.45M1.40M1.33M1.92M2.37M78.00K
Total Liabilities18.32M18.50M17.19M13.74M14.07M3.29M
Stockholders Equity26.55M24.53M26.34M32.34M46.70M1.53M
Cash Flow
Free Cash Flow2.60M-2.67M-6.71M-11.14M-2.92M-5.07M
Operating Cash Flow2.85M-2.40M-6.31M-10.69M-2.10M-4.80M
Investing Cash Flow-354.00K254.00K409.00K-260.00K-982.00K-263.00K
Financing Cash Flow-292.00K-620.00K-1.72M-1.35M46.64M1.99M

Sofwave Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2724.00
Price Trends
50DMA
2603.74
Positive
100DMA
2265.31
Positive
200DMA
1953.64
Positive
Market Momentum
MACD
21.08
Positive
RSI
52.02
Neutral
STOCH
59.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:SOFW, the sentiment is Positive. The current price of 2724 is below the 20-day moving average (MA) of 2827.70, above the 50-day MA of 2603.74, and above the 200-day MA of 1953.64, indicating a neutral trend. The MACD of 21.08 indicates Positive momentum. The RSI at 52.02 is Neutral, neither overbought nor oversold. The STOCH value of 59.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:SOFW.

Sofwave Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
969.00M
22.30%59.78%
51
Neutral
$7.93B-0.32-43.43%2.21%22.30%-1.88%
$298.61M38.139.62%
672.63M14.75
2.03%
33.06M
239.96M146.80
236.28M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IL:SOFW
Sofwave
2,724.00
954.00
53.90%
BRSYF
Brainsway
5.49
3.39
161.43%
IL:ILX
Ilex Medical
6,011.00
-34.92
-0.58%
IL:ALMD
Allmed Solution
34.50
-7.50
-17.86%
IL:EPIT
Epitomee Med
793.20
480.70
153.82%
IL:PULS
Pulsenmore
457.80
41.50
9.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025